Spanish researchers looking at two crucial proteins uncover how cells release mucin and insulin, leading to new methods to reset deregulation.
List view / Grid view
Chronic obstructive pulmonary disease (COPD)
US research about immunological memory may help development of potential vaccines or immunotherapies for cancer and various inflammatory diseases.
Researchers have genetically profiled nearly 200,000 cells from lungs, mapping their precise locations in tissue to discover an unexpected new immune niche in our airways.
Clarametyx says the FDA has accepted an IND application for first-in-human trials of CMTX-101, an antibody to treat bacterial pneumonia.
In this article, Patrick Kendall, Scientific Advisor for Artelo Biosciences, outlines why future treatment of cancer anorexia-cachexia syndrome may lie with drugs in development offering a mechanistic approach.
Scientists have developed an inhaled treatment for asthma that prevents excess mucus from building up in mice.
Study identifies a promising new compound that can open constricted airways and could be a promising treatment for obstructive lung diseases.
By blocking the lymphotoxin beta receptor signalling pathway, researchers were able to prevent COPD progression and induce a full restoration of lung tissue.
There are heightened levels of abnormal stem cells in the lungs of COPD patients, presenting a drug target that researchers are screening compounds against.
An innovation using artificial intelligence to analyse developing lung cell developments in vitro revealed what promotes them to develop and allowed researchers to create better quality lung tissue models.
Researchers have discovered that genetic variations in the anatomy of the lungs could serve as indicators to help identify people who are particularly at risk for COPD...
An antibody treatment has been found to reduce the rate of flare-ups by nearly 20 percent in patients with a subgroup of treatment-resistant COPD...
Prior to joining CRT-DL, Dr Ryder held positions in pharmaceutical and biotech companies for over 20 years ...